Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Leases Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Revenue - Other Shares Issued Shares Outstanding Shares Outstanding

Ratios

Artiva Biotherapeutics (ARTV) Shares Issued (2024 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Shares Issued for 2 consecutive years, with $138000.0 as the latest value for Q1 2025.

For Q1 2025, Shares Issued changed N/A year-over-year to $138000.0; the TTM value through Dec 2025 reached $138000.0, down 99.92%, while the annual FY2025 figure was $138000.0, 99.92% down from the prior year.
Shares Issued hit $138000.0 in Q1 2025 for Artiva Biotherapeutics, down from $166.5 million in the prior quarter.
Across five years, Shares Issued topped out at $166.5 million in Q3 2024 and bottomed at $138000.0 in Q1 2025.